Raj Tummala

TL;DR: Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect as discussed by the authors.

TL;DR: The efficacy of anifrolumab versus placebo in a phase 3 trial of adult patients with SLE and moderate-to-severe disease activity despite standard-of-care treatment was confirmed, and other measures of disease activity were assessed, including the British Isles Lupus Assessment Group-based composite lupus assessment (BICLA).

TL;DR: Combination of anxiety and depression is fairly common in a managed care population as evidenced by diagnosis and treatment, but the combination appears to increase the complexity of these patients with respect to comorbid conditions as well as increases the economic cost to payers.

TL;DR: In this paper, the authors validated the Lupus Low Disease Activity State (LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb randomised controlled trial (MUSE [NCT01438489]) and then utilized LLDAS to discriminate between anifrolumab and placebo.

TL;DR: Although the primary endpoint was not met, anifrolumab IR was associated with numerical improvements over placebo across endpoints, including CRR, in patients with active lupus nephritis.